Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New stomach cancer therapy potentially more convenient and better tolerated

18.05.2005


Data suggest that it may pack an improved punch against gastric cancer



A new combination chemotherapy appears to battle advanced stomach cancer harder than other platinum-based therapies, while offering patients more convenience and potentially less discomfort, according to results announced at the 2005 Annual Meeting of the American Society of Clinical Oncology. Researchers studied the combination of a new drug, called S-1, and the platinum-based chemotherapy called cisplatin in patients with advanced gastric cancer.

Overall, 13 of the 20 patients (65 percent) evaluated so far in the phase II trial responded to the chemotherapy. That means tumors shrank in response to the drug. "We believe the therapy has the potential to not only fight cancer more effectively, but also is easier for cancer patients to deal with," says study co-author and medical oncologist Heinz-Josef Lenz, M.D., associate professor of medicine at the Keck School of Medicine of the University of Southern California and USC/Norris Comprehensive Cancer Center.


The study was presented at ASCO by Jaffer A. Ajani, M.D., professor in gastrointestinal medical oncology at University of Texas/M.D. Anderson Cancer Center.

In 2005, experts estimate that 21,860 Americans will be diagnosed with stomach cancer during 2005 and another 11,550 will die from the disease.

In addition to surgery, physicians today use a variety of chemotherapy drugs against stomach cancer. Yet researchers have not found a standard chemotherapy regimen that dramatically improves survival more than any other.

One commonly used drug is the traditional chemotherapy called 5-FU (5-fluorouracil). Studies have shown that when cisplatin is combined with 5-FU, cancer shrinks in 46 percent to 51 percent of stomach cancer patients. The combination of S-1 and cisplatin aims to take that a step further.

S-1 consists of a number of parts. One portion of S-1 actually breaks down into 5-FU in the body. At the same time, it contains another element that keeps levels of 5-FU fairly steady in the body, reducing the ups and downs of chemotherapy. It contains a third element, too, that fights 5-FU’s toxic effects in gastrointestinal tissues-a cause of chemotherapy nausea and vomiting. Finally, it is available in a capsule, instead of through an intravenous infusion, making it more convenient for patients.

In this study, patients received an infusion of cisplatin on the first day of treatment, then took S-1 twice a day every day for three weeks, and took a week off to recover before starting the cycle all over again.

In all, 41 patients participated and were evaluable; researchers have examined information on the drug’s safety in 30 patients and on the drug’s effectiveness in 20 patients. In the 13 patients whose cancer responded to the drug, tumors began growing again about 4.8 months after treatment.

Lenz is optimistic about the drug’s potential. "At USC/Norris, we established the genetic profile giving the rationale for this drug, so we understand how and why it works," he says. He noted that another early study in Japan of S-1 and cisplatin for advanced gastric cancer showed 19 of 25 patients, or 76 percent, responded to the drug.

The most common side effects were fatigue, nausea and anorexia.

S-1 is under development by Taiho Pharma USA Inc.

Jon Weiner | EurekAlert!
Further information:
http://www.usc.edu

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

New gene catalog of ocean microbiome reveals surprises

18.08.2017 | Life Sciences

Astrophysicists explain the mysterious behavior of cosmic rays

18.08.2017 | Physics and Astronomy

AI implications: Engineer's model lays groundwork for machine-learning device

18.08.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>